

SECURITIES AND EXCHANGE COMMISSION

FORM 8-K

Current report filing

Filing Date: **2013-01-10** | Period of Report: **2013-01-09**  
SEC Accession No. [0001193125-13-008441](#)

([HTML Version](#) on [secdatabase.com](#))

FILER

**Sarepta Therapeutics, Inc.**

CIK: **873303** | IRS No.: **930797222** | State of Incorp.: **OR** | Fiscal Year End: **1231**  
Type: **8-K** | Act: **34** | File No.: **001-14895** | Film No.: **13521427**  
SIC: **2834** Pharmaceutical preparations

Mailing Address  
3450 MONTE VILLA  
PARKWAY  
SUITE 101  
BOTHELL WA 98021

Business Address  
3450 MONTE VILLA  
PARKWAY  
SUITE 101  
BOTHELL WA 98021  
425-354-5038

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, DC 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): January 9, 2013**

---

**Sarepta Therapeutics, Inc.**

(Exact name of registrant as specified in its charter)

---

**Oregon**  
(State or other jurisdiction  
of incorporation)

**001-14895**  
(Commission  
File Number)

**93-0797222**  
(IRS Employer  
Identification No.)

**3450 Monte Villa Parkway, Suite 101  
Bothell, WA 98021**  
(Address of principal executive offices, including zip code)

**(425) 354-5038**  
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

---

**Item 2.02 Results of Operations and Financial Condition.****Item 7.01 Regulation FD Disclosure.**

*The information in this report furnished pursuant to Items 2.02 and 7.01 shall not be deemed "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Items 2.02 and 7.01 of this report.*

At an investor conference on January 9, 2013, Sarepta Therapeutics, Inc. disclosed that its cash balance as of December 31, 2012 was approximately \$187 million.

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**Sarepta Therapeutics, Inc.**

By: /s/ Christopher Garabedian

Christopher Garabedian

President and Chief Executive Officer

Date: January 9, 2013